Enhanced spontaneous thrombolysis: A new therapeutic challenge

Journal of Thrombosis and Thrombolysis

Volumn 21, Issue 3, 2006, Pages 221-227

  Kovacs, I B ^a   Gorog, D A ^b   Yamamoto, J ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Fibrinolysis; Platelets; Thrombolysis; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BIGUANIDE DERIVATIVE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PHENFORMIN; SIMVASTATIN; TICLOPIDINE; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FIBRINOLYSIS; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; CORONARY THROMBOSIS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION;

EID: 33646432272     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-6579-0     Document Type: Article

References (96)

1. Swan HJ (1989) Acute myocardial infarction: A failure of timely, spontaneous thrombolysis. J Am Coll Cardiol 13:1435-1437
2. Osterlund B, Andersson B, Haggmark S et al. (2002) Myocardial ischemia induces coronary t-PA release in the pig. Acta Anaesthesiol. Scand 46:271-278
3. Johansson L, Jansson JH, Boman K (2000) Tissue plasminogen activator, plasminogen activator inhibitor and tissue plasminogen activator/ plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31:26-32
4. DeWood MA, Spores J, Notske R (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897-902
5. Sanborn TA, Faxon DP, Kellett MA (1983) Serial angiographic evidence of rapid resolution of coronary artery stenosis. Chest 84:302-304
6. Zingerman LS, Golikov AP, Topchiian GS (1988) The possibility of spontaneous lysis of a coronary thrombus patient, with acute myocardial infarct. Kardioologiia 28:24-28
7. Christian TF, Milavetz, JJ, Miller TD (1998) Prevalence of spontaneous reperfusion and associated myocardial salvage in patients with acute myocardial infarction. Am Heart J 135:421-427
8. Lee CW, Hong MK, Lee JH (2001) Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. Am J Cardiol 87:951-953
9. Seibert CE, Swanson WB (1976) Lysis of thrombus in internal carotid artery in the neck. Report of a case. Acta Radiol Suppl, 347:271-275
10. Engel HJ, Lichtlen P (1977) Indications for a spontaneous lysis in the human coronary system - coronary stenosis as a dynamic process? Verh Dtsch Ges Inn. Med 83:245-249
11. Weiner MA, Sniderman KW, Sos TA (1984) Two cases of spontaneous lysis of arterial thrombi. Cardiovasc Intervent Radiol 7:24-27
12. Weber W, Hotker U, Schild H (1989) Spontaneous arterial recanalization - a case report. Rontgenblatter 42:172-173
13. Chen LE, Seaber AV, Urbaniak JR (1996) Thrombosis and thrombolysis in crushed arteries with or without anastomosis: A new microvascular model. Reconstr Microsurg 12:31-38.
14. Schini-Kerth VB (1999) Vascular biosynthesis of nitric oxide: Effect on hemostasis and fibrinolysis. Transfus Clin Biol 6:355-363
15. Rosenhek R, Korschineck I, Gharehbaghi-Schnell E (2003) Fibrinolytic balance of the arterial wall: Pulmonary artery displays increased fibrinolytic potential compared with aorta. Lab Invest 83:871-876
16. Zeng B, Bruce D, Kril J (2002) Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: studies in plasminogen knock-out mice. Thromb Haemost 88:805-810
17. Burnand KG, Gaffney PJ, McGuinness CL (1998) The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg 6:119-125
18. Jang IK, Gold HK, Ziskind AA (1989) Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 79:920-928
19. Niessen F, Hilger T, Hoehn M et al. (2003) Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke 34:2019-2024
20. Torr-Brown SR, Sobel BE (1993) Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 72:413-421
21. Robbie LA, Bennett B, Croll AM (1996) Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 75:127-133
22. Fay WP, Murphy JG, Owen WG (1996) High concentrations of active plasminogen activator inhibitor in porcine coronary artery thrombi. Arterioscler. Thromb Vasc Biol 16:1277-1284
23. Mosnier LO, Buijtenhuijs P, Marx PF (2003) Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 101:4844-4846
24. Moir E, Booth NA, Bennett B, Roppic LA. (2001) Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 113:72-80
25. Taylor FB Jr, Lockhart MS (1985) Whole blood clot lysis: In vitro modulation by activated protein C. Thromb Res 37:639-649
26. Wun TC, Capuano A (1985) Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro. J Biol Chem 260:5061-5066
27. Glassman A, Abram M, Baxter G, Swett A (1993) Euglobulin lysis times: An update. Ann Clin Lab Sci 23:329-332
28. Boudjeltia KZ, Cauchie P, Remacle CM (2002) A new device for measurement of fibrin clot lysis: Application for the Euglobulin Clot Lysis Time. BMC. Biotechnol 2:8.
29. Soeki T, Tamura Y, Shinohara H (2002) Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death. Int J Cardiol 85:277-283
30. Jansson JH, Olofsson BO, Nilsson TK (1993) Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation 88:2030-2034
31. Geppert A, Graf S, Beckmann R (1998) Concentration of endogenous tPA antigen in coronary artery disease: Relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol 18:1634-1642
32. Ver Elst K, Jochmans K, De Pauw A, et al. (2002) Plasma D-dimer concentrations in different clinical conditions. Acta Clin Belg 57:325-330
33. Pedersen OD, Gram J, Jespersen J (1995) Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemost 73:835-840
34. Kwaan HC, Nabhan C (2003) Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin North Am 17:103-114
35. Juhan-Vague I, Morange PE, Aubert H (2002) Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 22:867-873
36. Lijnen HR (2001) Gene targeting in hemostasis. Alpha2-antiplasmin. Front Biosci 6: D239-47
37. Stegnar M, Uhrin P, Peternel P (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 gene: Relationship to plasma PAI-1 levels in venous thromboembolism. Thromb Haemost 79:975-979
38. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M (2003) Plasminogen activator inhibitor-1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: Impaired fibrinolysis and early pregnancy loss. Clin Chem 49:1081-1086
39. Hoekstra T, Geleijnse JM, Kluft C (2003) 4G/4G Genotype of PAI-1 is associated with reduced risk of stroke in elderly. Stroke 34:2822-2828
40. Menon IS (1970) Aspirin and blood fibrinolysis. Lancet 1:364.
41. Moroz LA (1977) Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 296:525-529
42. Bjornsson TD, Schneider DE, Berger H Jr (1989) Aspirin acetylates fibrinogen and enhances fibrinolysis. J Pharmacol Exp Ther 250:154-161
43. Milwidsky A, Finci-Yeheskel Z, Mayer M (1991) Stimulation of plasmin by aspirin. Thromb Haemostas 65:389-393
44. Levin RI, Harpel PC, Harpel JG, et al. (1989) Inhibition of tissue plasminogen activator activity by aspirin in vivo. Blood 74:1635-1643
45. Keber I, Jereb M, Keber D (1987) Aspirin decreases fibrinolytic potential during venous occlusion but not during acute physical activity. Thromb Res 46:205-212
46. Levin RI, Harpel PC, Weil D, et al. (1984) Aspirin inhibits plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest 74:571-580
47. Winther K, Gleerup G, Husted S (1994) Do low and moderate doses of acetylsalicylic acid affect tissue plasminogen activator at rest and after exercise? Am J Cardiol 73:703-705
48. Husted SE, Kristensen SD, Vissinger H, et al. (1992) Intravenous acetylsalicylic acid-dose related effects on platelet function and fibrinolysis in healthy males. Thromb Haemost 68:226-229
49. Gum PA, Kottke-Marchant K, Poggio ED (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
50. Gryglewski RJ, Korbut R, Swies J, et al. (1996) Thrombolytic action of ticlopidine: Possible mechanisms. Eur J Pharmacol 308:61-67
51. Slavina NN, Averkov OV, Dobrovolskii AB, et al. (2003) Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel. Kardiologiia 43:4-11
52. Taher TH, Stang L, Gordon PA, et al. (2004) Armstrong PW. Clopidogrel does not induce fibrinolysis in healthy subjects. Thromb Res 114:97-100
53. Moser M, Bertram U, Peter K, et al. (2003) Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 41:586-592
54. Sobel BE (2003) Fibrinolysis and diabetes. Front Biosci 8:d1085-92
55. Chiquette E, Chilton R (2002) Cardiovascular disease: Much more aggressivein patients with type 2 diabetes. Curr Atheroscler Rep 4:134-142
56. Libby P (2003) Metformin and vascular protection: A cardiologist's view. Diabetes Metab 29:6S117-120
57. Panunti B, Kunhiraman B, Fonseca V (2005) The impact of antidiabetic therapies on cardiovascular diseases. Curr Atheroscler Rep 7:50-57
58. Vaughan, D.E (1998) Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease. Eur Heart J 19, Suppl G:G9-12
59. Ludwig S, Dharmalingam S, Erickson-Nesmith S, et al. (2005) Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. Diabetes Res Clin Pract 70: 110-118
60. Malyszko JS, Hryszko T, Mysliwiec M (2003) Influence of simvastatin on aspects of thrombogenesis in CAPD patients. Perit Dial Int 23:260-266
61. John S, Schneider MP, Delles C, et al. (2005) Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 149:473-485
62. Undas A, Celinska-Lowenhoff M, Kaczor M, et al. (2004) New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 91:1065-1077
63. Krysiak R, Okopien B, Herman Z (2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolytic processes. Drugs 63:1821-1854
64. Sanguigni V, Pignatelli P, Lenti L, et al. (2005) Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circ 111(4):412-419
65. Yamakuchi M, Greer JJ, Cameron SJ, et al. (2005) HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 96:1185-1192
66. Singh U, Devaraj S, Jialal I (2005) C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 25:2216-2221
67. Nissen SE (2005) Effect of intensive lipid lowering on progression of coronary atherosclerosis: Evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 96(5A):61F-68F
68. Kinjo K, Sato H, Sakata Y, et al. (2005) Osaka Acute Coronary Insufficiency Study (OACIS) Group. Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. Am J Cardiol 96:617-621
69. Yamamoto, J, Yamashita T, Ikarugi H, et al. (2003) Thrombosis Test: A global in vitro test of platelet function and thrombolysis. Blood Coagul. Fibrinolysis 14:31-39
70. Yamamoto J, Kovacs IB (2003) Shear-induced in vitro haemostasis/ thrombosis tests: The benefit of using native blood. Blood Coagul Fibrinolysis 14:697-702
71. Ikarugi H, Yamashita T, Aoki R (2003) Impaired spontaneous thrombolytic activity in elderly and in habitual smokers, as measured by a new global thrombosis test. Blood Coagul. Fibrinolysis 14:781-784
72. Yamashita T, Sato A, Ikarugi H. Significantly reduced spontaneous thrombolytic activity in elderly men: A possible explanation for gender differences in risk of acute coronary syndromes (Thromb. Res., in press).
73. Gils A, Declerck PJ (2004) The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors. Thromb Haemost 91:425-437
74. van Giezen JJ, Wahlund G, Abrahamsson T. (1997) The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb Haemost 77:964-969
75. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. (1995) Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 91:1175-1181
76. Eitzman DT, Fay WP, Lawrence DA, et al. (1995) Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 95:2416-2420
77. Charlton PA, Faint RW, Bent F, (1996) Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 75:808-815
78. Friederich PW, Levi M, Biemond BJ, et al. (1997) Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 96:916-921
79. Carmeliet P, Stassen JM, Schoonjans L, et al. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756-2760
80. Chavakis T, Pixley RA, Isordia-Salas I, Colman RW, Preissner KT. (2002) A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J Biol Chem 277:32677-32682
81. Hennan JK, Elokdah H, Leal M, et al. (2005) Evaluation of PAI-039 1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 314:710-716
82. Suzuki K, Muto Y, Fushihara K, et al. (2004) Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2- [(R)-2-methyl-1-(3-phenylpropanoylamino)propyl ]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase Br J Pharmacol Exp Ther 309:607-615
83. Nair CH., Azhar A, Wilson JD., Dhall DP. (1991) Studies on fibrin network structure in human plasma. Thromb Res 64:477-485
84. Williams F, Fatah K, Hjemdahl P, Blomback M. (1998) Better increase in fibrin gel porosity by low dose than intermediate does acetylsalicylic acid. Eur Heart J 19:1666-1672
85. Manganaro A, Ruggeri M, Ando G, Longo M, Vita G. (2002) Endothelial functions in pathophysiology of thrombosis and fibrinollysis: Late spontaneous recanalization of an occluded internal carotid artery - a case report. Angiology 53:99-103
86. Kim JA, Tran ND, Zhou W, Fisher M. (2005) Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res 115:435-438
87. Lin Z, Kumar A, SenBanerjee S, Staniszewski P, Parmar K, Vaughan DE, Gimbrone MA Jr, Balasubramanian V, Garcia-Gardena G, Jain MK. (2005) Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res 96:e48-57
88. Marchetti M, Vignoli A, Bani MR, Balducci D, Barbui T, Falanga A. (2003) All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica 88:895-905
89. Chen PR, Lee CC, Chang H, Tsai CE. (2005) Sesamol regulates plasminogen activator gene expression in cultured endothelial cells: A potential effect on the fibrinolytic system. J Nutr Biochem 16:59-64
90. Markle RA, Han J, Summers BD, et al. (2003) Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 90:23-32
91. Carmeliet P, Stassen JM, Van Vlaenderen L, Meidell RS, Collen D, Gerard RD. (1997) Adenovirus-mediated transfer if tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 90:1527-1534
92. Ozuyaman B, Ebner P, Nielsner U, et al. (2005) Nitric oxide differentially regulates proliferation and mobilization of endothelial progenitor cells but not of hematopoietic stem cells. Thromb Haemost 94:770-772
93. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenhaler M, Anker SD, Poole-Wilson PA, Ertl G, Bauersachs J. (2005) Supression of endothelial progenitor cells in human coronary artery disease by endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 46:1693-1701
94. Fadini GP, Miorin M, Facco M, et al. (2005) Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45:1449-1457
95. Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. (2005) Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol 45:1441-1448
96. Michaud SE, Dussault S, Haddad P, Groleau J, Rivard A. (2005) Circulating endothelial progenitor cells from healthy smokers exhibit impaired functional activities. Atherosclerosis Nov 7